Pfiz­er ax­es sick­le cell, be­ta tha­lassemia deal with Sy­ros

Pfiz­er ter­mi­nat­ed a deal that Sy­ros Phar­ma­ceu­ti­cals made with Glob­al Blood Ther­a­peu­tics to de­vel­op treat­ments for be­ta tha­lassemia and sick­le cell dis­ease.

Pfiz­er ac­quired GBT last year for $5.4 bil­lion.

Un­der the agree­ment from 2019, GBT had an ex­clu­sive li­cense to de­vel­op and com­mer­cial­ize any com­pounds that re­sult­ed from the Sy­ros col­lab­o­ra­tion. Sy­ros is cur­rent­ly de­vel­op­ing can­di­dates for dif­fer­ent types of can­cer, in­clud­ing myelodys­plas­tic syn­dromes and acute myeloid leukemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER